相似文献
1
Efficacy and safety of donepezil in patients with Alzheimer's disease in assisted living facilities.
Am J Alzheimers Dis Other Demen. 2010 Sep;25(6):483-9. doi: 10.1177/1533317510372923. Epub 2010 Jun 17.
2
Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.
Drugs Aging. 2004;21(1):43-53. doi: 10.2165/00002512-200421010-00004.
3
A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
J Am Geriatr Soc. 2001 Dec;49(12):1590-9.
4
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.
BMC Res Notes. 2012 Jun 8;5:283. doi: 10.1186/1756-0500-5-283.
5
Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.
Int J Geriatr Psychiatry. 2000 Aug;15(8):713-20. doi: 10.1002/1099-1166(200008)15:8<713::aid-gps187>3.0.co;2-i.
6
A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia.
Am J Alzheimers Dis Other Demen. 2009 Aug-Sep;24(4):293-301. doi: 10.1177/1533317509334960. Epub 2009 Apr 21.
7
Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
Curr Med Res Opin. 2002;18(6):347-54. doi: 10.1185/030079902125001029.
8
Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Neurology. 2007 Jul 31;69(5):459-69. doi: 10.1212/01.wnl.0000266627.96040.5a.
9
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
Clin Ther. 2010 Jul;32(7):1234-51. doi: 10.1016/j.clinthera.2010.06.019.
10
Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study.
Int J Med Sci. 2012;9(3):248-55. doi: 10.7150/ijms.4363. Epub 2012 May 7.
引用本文的文献
1
Changes in Antidementia Medications upon Admission to the Nursing Home: Who Decides and Why? Results From a National Survey of Nursing Home Administrators.
J Am Med Dir Assoc. 2024 Jan;25(1):41-46.e5. doi: 10.1016/j.jamda.2023.09.022. Epub 2023 Oct 28.
2
Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease.
Am J Alzheimers Dis Other Demen. 2012 Sep;27(6):421-32. doi: 10.1177/1533317512454708.
本文引用的文献
1
Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials.
Curr Med Res Opin. 2009 Nov;25(11):2577-87. doi: 10.1185/03007990903236731.
2
Realistic expectations for treatment success in Alzheimer's disease.
J Nutr Health Aging. 2006 Sep-Oct;10(5):417-29.
3
Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors.
J Gerontol A Biol Sci Med Sci. 2006 May;61(5):516-20. doi: 10.1093/gerona/61.5.516.
4
Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
Lancet. 2006 Apr 1;367(9516):1057-1065. doi: 10.1016/S0140-6736(06)68350-5.
5
Evaluation of demographics and medication use in patients with dementia in assisted living and skilled nursing facilities.
Consult Pharm. 2005 Jul;20(7):584-94. doi: 10.4140/tcp.n.2005.584.
6
Underrecognition of cognitive impairment in assisted living facilities.
J Am Geriatr Soc. 2005 Feb;53(2):295-8. doi: 10.1111/j.1532-5415.2005.53117.x.
7
Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
J Am Geriatr Soc. 2005 Jan;53(1):83-7. doi: 10.1111/j.1532-5415.2005.53015.x.
8
Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.
Arch Neurol. 2004 Dec;61(12):1852-6. doi: 10.1001/archneur.61.12.1852.
9
Impact of rivastigmine use on the risk of nursing home placement in a US sample.
CNS Drugs. 2004;18(15):1143-8. doi: 10.2165/00023210-200418150-00008.
10
The Maryland Assisted Living Study: prevalence, recognition, and treatment of dementia and other psychiatric disorders in the assisted living population of central Maryland.
J Am Geriatr Soc. 2004 Oct;52(10):1618-25. doi: 10.1111/j.1532-5415.2004.52452.x.
Zotero 插件